Kevin Kratiuk

Vice President, Operations at Braxia Health Clinics

Data updated

Papers

6 publications

Trials

0 clinical trials

Links

Website

Research Footprint

Kevin Kratiuk appears in 6 tracked papers (2021–2024), most studied alongside Ketamine, Psilocybin and Esketamine, across Depressive Disorders, Suicidality and Treatment-Resistant Depression (TRD).

Most-cited paper: Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation (676 citations).

Frequent co-authors: Roger McIntyre, Jonathan Rosenblat and Rodrigo Mansur.

Background & Research

Kevin Kratiuk is the Vice-President of Operations at Braxia Health Clinics and has held that role since July 2018. He earned a Doctor of Pharmacy degree from Poznan University of Medical Sciences in 2014 and also founded KJK Health, which includes a family practice clinic and KJK Pharmacy. Braxia describes him as having provided medical education consults since 2010 to more than 1,000 Canadian medical students studying abroad.

Key Impact

He appears as a recurring author on ketamine and psilocybin clinical research from Braxia Health/CRTCE, contributing to translational and real-world psychedelic psychiatry studies.

6

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

27 collaborators· click a node to visit their profile

Full network →

Compounds

KetaminePsilocybinEsketamine

Topics

Depressive DisordersSuicidalityTreatment-Resistant Depression (TRD)Anxiety DisordersMajor Depressive Disorder (MDD)AdolescentsBipolar DisorderPersonality DisordersPublic Health, Prevention & Behaviour ChangeNeurocognitive DisordersSubstance Use Disorders (SUD)SchizophreniaSafety & Risk ManagementBorderline Personality Disorder (BPD)

Top Collaborators

Affiliations

Institutions, companies, and organisations Kevin Kratiuk is associated with.

Braxia Scientific Corp.

Public Biotech

Braxia Scientific Corp. (CSE: BRAX) is a Canadian publicly-listed medical research company that operates a network of ketamine and psilocybin treatment clinics across Ontario and Quebec through its subsidiary Canadian Rapid Treatment Centre of Excellence, and conducted Canada's first multi-dose Phase II psilocybin randomized controlled trial for treatment-resistant depression. The company received Health Canada Special Access Program approval to deliver psilocybin-assisted therapy in Ontario and holds government-funded grants for ketamine trials in bipolar depression, led by researchers Dr. Roger McIntyre and Dr. Joshua Rosenblat.

View stakeholder →